Yutiq Fluocinolone Acetonide Intravitreal Implants

1. Indications and Usage
Diabetic Macular Edema (DME):
Treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
Non-Infectious Posterior Uveitis:
Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
2. Dosage and Administration
Route of Administration:
For Intravitreal Injection ONLY. Must be administered by an ophthalmologist.
Recommended Dosage:
Dose: One implant (containing 0.19 mg or 0.18 mg depending on region/version).
Frequency: Once every 3 years (36 months), as the implant is designed for continuous release over this period.
Readministration: If symptoms recur after 36 months, a second implant may be considered.
Critical Administration Instructions:
Sterile Technique: Administer under sterile conditions with appropriate anesthesia and topical broad-spectrum bacteriostatic agent.
Injection Site: Typically injected into the vitreous cavity (e.g., 4 mm posterior to the limbus).
3. Mechanism of Action
Corticosteroid Activity:
Fluocinolone acetonide is a potent synthetic glucocorticoid.
Anti-Inflammatory & Anti-Edema Effects:
It inhibits the release of substances that sustain the inflammatory and edematous response. It stabilizes lysosomal membranes, reduces capillary permeability, and inhibits leukocyte migration and fibroblast proliferation.
Therapeutic Result: Reduces retinal edema and inflammation, thereby improving or stabilizing visual acuity.
Sustained Release:
The implant is a non-biodegradable micro-catheter that releases the drug at a constant low rate (e.g., ~0.2–0.5 µg/day) directly into the vitreous.
4. Safety and Warnings
Elevated Intraocular Pressure (IOP):
Corticosteroids may cause a clinically significant rise in IOP, which can lead to optic nerve damage and glaucoma.
Action: Monitor IOP at appropriate intervals.
Cataract Formation:
Prolonged use of corticosteroids may accelerate cataract formation (specifically posterior subcapsular cataracts).
Endophthalmitis:
As with any intravitreal injection, there is a risk of intraocular infection (endophthalmitis).
Contraindications:
Active or suspected ocular or periocular infections (e.g., viral keratitis).
Patients with glaucoma or IOP > 18 mmHg not controlled by medication.
Hypersensitivity to the drug.
5.Adverse Reactions
Most Common:
Cataract progression, elevated intraocular pressure, vitreous hemorrhage, vitreous floaters, and conjunctival hemorrhage.
6.Drug Interactions
No Clinical Significance:
As a locally acting protein/steroid, systemic drug interactions are not expected. However, concomitant use with other ocular steroids increases the risk of IOP elevation.
7.Pharmaceutical Information
Chemical Composition:
Active Ingredient: Fluocinolone Acetonide.
Appearance: Small, non-biodegradable, pre-loaded applicator.
Storage: Store below 25°C (77°F). Protect from light.